CDRH Postmarket Surveillance Final Rule To Take Effect July 8
This article was originally published in The Gray Sheet
Executive Summary
FDA approval need only be obtained for "significant" changes to approved postmarket surveillance (PS) studies, the agency clarifies in a 1June 6 final rule